Cargando…

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

The anti-HER2 antibody Trastuzumab (Herceptin) has been proven to be effective in the treatment of HER2 overexpressing breast cancer; resistance, however invariably emerges in metastatic tumors. The expression of p95-HER2, a form of HER2 with a truncated extracellular domain that lacks the Trastuzum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chandarlapaty, Sarat, Scaltriti, Maurizio, Angelini, Pierdavide, Ye, Qing, Guzman, Marta, Hudis, Clifford A., Norton, Larry, Solit, David B., Arribas, Joaquin, Baselga, Jose, Rosen, Neal
Formato:	Texto
Lenguaje:	English
Publicado:	2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057066/ https://www.ncbi.nlm.nih.gov/pubmed/19855434 http://dx.doi.org/10.1038/onc.2009.337

Ejemplares similares

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer
por: Jhaveri, Komal, et al.
Publicado: (2017)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Smith, Alison E., et al.
Publicado: (2021)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
por: Serra, V, et al.
Publicado: (2011)

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
por: Hudis, Clifford, et al.
Publicado: (2013)

Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism
por: Fuentes, Gloria, et al.
Publicado: (2011)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
por: Lopez-Albaitero, Andres, et al.
Publicado: (2017)

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
por: Park, Jung Min, et al.
Publicado: (2020)

Heat Shock Protein 90 (HSP90) and Her2 in Adenocarcinomas of the Esophagus
por: Slotta-Huspenina, Julia, et al.
Publicado: (2014)

TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS
por: Raina, Deepak, et al.
Publicado: (2013)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

Progress towards the United Nations 90‐90‐90 and 95‐95‐95 targets: the experience in British Columbia, Canada
por: Lima, Viviane D., et al.
Publicado: (2017)

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen
por: Kong, Anthony, et al.
Publicado: (2016)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Association between HSP90 and Her2 in Gastric and Gastroesophageal Carcinomas
por: Berezowska, Sabina, et al.
Publicado: (2013)

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
por: Yang, C, et al.
Publicado: (2017)

Modelling the epidemiologic impact of achieving UNAIDS fast-track 90-90-90 and 95-95-95 targets in South Africa
por: Abuelezam, N. N., et al.
Publicado: (2019)

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
por: She, Qing-Bai, et al.
Publicado: (2008)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
por: Baselga, J., et al.
Publicado: (2019)

Pilot study of (68)Ga-DOTA-F(ab′)(2)-trastuzumab in patients with breast cancer
por: Beylergil, Volkan, et al.
Publicado: (2013)

Fortran 90/95 explained
por: Metcalf, Michael, et al.
Publicado: (2002)

Fortran 90/95 explained
por: Metcalf, Michael, et al.
Publicado: (1990)

Essential Fortran 90 and 95
por: Meissner, Loren P
Publicado: (1997)

Fortran 90/95 Explained
por: Metcalf, Michael, et al.
Publicado: (1996)

Hsp90 inhibition and co‐incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T‐DM1
por: Skeie, Marianne, et al.
Publicado: (2020)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
por: Mateo, Lidia, et al.
Publicado: (2020)

Specific Roles of HSP27 S15 Phosphorylation Augmenting the Nuclear Function of HER2 to Promote Trastuzumab Resistance
por: Hwang, Soo-Yeon, et al.
Publicado: (2020)

Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
por: Moss, Nelson S., et al.
Publicado: (2023)

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
por: Park, Soeun, et al.
Publicado: (2021)

Fortran 90/95 for scientists and engineers /
por: Chapman, Stephen J.
Publicado: (2004)

Fortran 90/95 for scientists and engineers
por: Chapman, Stephen J
Publicado: (1998)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Mechanisms of Hsp90 regulation
por: Prodromou, Chrisostomos
Publicado: (2016)

Regulatory Mechanisms of Hsp90
por: Prodromou, Chrisostomos
Publicado: (2017)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Role of HSP90 in Cancer
por: Birbo, Bereket, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8lod5aes0drq7cfr6kbflt4dkv